CendR Platform® Technology
The CendR Platform® incorporates novel technologies to enable more effective tumor-targeted, tissue penetrating delivery of anti-cancer drugs to solid tumors. The Platform can also target non-cancerous, immunosuppressive cells selectively within the tumor to enable a patient’s immune system and/or immunotherapies to fight cancer more effectively.
Broad, Clinical-Stage Pipeline
We aim to transform patient lives through the development of unique therapies targeting cancer and other serious diseases.
Join Our Team
Our mission is to discover, develop and deliver innovative therapies for the treatment of advanced solid tumors and other major diseases. We can accomplish that goal through the collective efforts of talented individuals who work together to advance scientific research. We place a premium on integrity, respect, diversity, and collaboration. These values have helped us to build a growing company that offers professionally rewarding careers with the opportunity to make a meaningful contribution to patients in need.
Dr. David J. Mazzo, Lisata’s President and CEO, has been named a PharmaVoice 100 Standout Leader. This prestigious recognition highlights Dr. Mazzo’s exceptional leadership and commitment to driving innovation in the life sciences industry.